AstraZeneca officially receives license for production of drugs in Russia
Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has officially received a license for the production of drugs in Russia at its local plant, that will be soon be commissioned in the Vorsino industrial park in the Kaluga region.
According to the company, to date, building of the first stage of the plant has almost been completed. The value of investments in the project at the initial stage is expected to reach $223 million. The plant will be commissioned by the end of the current year.
The new plant will have the capacity to produce 25 million packages of drugs per year, while its range will be comprised of almost 30 innovative drugs, which will be mostly designed for the treatment of diseases in such fields as cardiology, oncology, psychiatry, gastroenterology and pulmonology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze